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Hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) 
differ in treatment and prognosis, warranting an effective differential diagnosis 
between them. The LR-M category in the contrast-enhanced ultrasound (CEUS) 
liver imaging reporting and data system (LI-RADS) was set up for lesions that are 
malignant but not specific to HCC. However, a substantial number of HCC cases 
in this category elevated the diagnostic challenge.
AIM 
To investigate the possibility and efficacy of differentiating ICC from HCC 
classified in the LR-M category according to the CEUS LI-RADS.
METHODS 
Patients with complete CEUS records together with pathologically confirmed ICC 
and LR-M HCC (HCC classified in the CEUS LI-RADS LR-M category) between 
January 2015 and October 2018 were included in this retrospective study. Each 
ICC was assigned a category as per the CEUS LI-RADS. The enhancement pattern, 
washout timing, and washout degree between the ICC and LR-M HCC were 
compared using the χ2 test. Logistic regression analysis was used for prediction of 
ICC. Receiver operating characteristic (ROC) curve analysis was used to 
investigate the possibility of LR-M criteria and serum tumor markers in 
differentiating ICC from LR-M HCC.
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RESULTS 
A total of 228 nodules (99 ICCs and 129 LR-M HCCs) in 228 patients were 
included. The mean sizes of ICC and LR-M HCC were 6.3 ± 2.8 cm and 5.5 ± 3.5 
cm, respectively (P = 0.03). Peripheral rim-like arterial phase hyperenhancement 
(APHE) was detected in 50.5% (50/99) of ICCs vs 16.3% (21/129) of LR-M HCCs (
P < 0.001). Early washout was found in 93.4% (93/99) of ICCs vs 96.1% (124/129) 
of LR-M HCCs (P > 0.05). Marked washout was observed in 23.2% (23/99) of ICCs 
and 7.8% (10/129) of LR-M HCCs (P = 0.002), while this feature did not show up 
alone either in ICC or LR-M HCC. Homogeneous hyperenhancement was 
detected in 15.2% (15/99) of ICCs and 37.2% (48/129) of LR-M HCCs (P < 0.001). 
The logistic regression showed that rim APHE, carbohydrate antigen 19-9 (CA 19-
9), and alpha fetoprotein (AFP) had significant correlations with ICC (r = 1.251, 
3.074, and -2.767, respectively; P < 0.01). Rim APHE presented the best 
enhancement pattern for diagnosing ICC, with an area under the ROC curve 
(AUC) of 0.70, sensitivity of 70.4%, and specificity of 68.8%. When rim 
hyperenhancement was coupled with elevated CA 19-9 and normal AFP, the AUC 
and sensitivity improved to 0.82 and 100%, respectively, with specificity 
decreasing to 63.9%.
CONCLUSION 
Rim APHE is a key predictor for differentiating ICC from LR-M HCC. Rim APHE 
plus elevated CA 19-9 and normal AFP is a strong predictor of ICC rather than 
LR-M HCC. Early washout and marked washout have limited value for the 
differentiation between the two entities.
Key words: Diagnosis; Contrast enhanced ultrasound; Hepatocellular carcinoma; 
Intrahepatic cholangiocarcinoma; Liver imaging reporting and data system
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Core tip: Hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) 
differ in treatment and prognosis, warranting an effective differential diagnosis between 
them. The LR-M category in the contrast-enhanced ultrasound liver imaging reporting and 
data system was set up for lesions that are malignant but not specific to HCC. Our study 
demonstrated that rim arterial phase hyperenhancement (APHE) is a key predictor for 
differentiating ICC from LR-M HCC, whereas early washout and marked washout have 
limited value for differentiating them. Rim APHE plus elevated carbohydrate antigen 19-9 
and normal alpha fetoprotein is a strong predictor of ICC rather than LR-M HCC.
Citation: Huang JY, Li JW, Ling WW, Li T, Luo Y, Liu JB, Lu Q. Can contrast enhanced 
ultrasound differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma? World 




Liver cancer is the sixth most common cancer worldwide and the fourth leading cause 
of cancer-related death[1]. Hepatocellular carcinoma (HCC) and intrahepatic 
cholangiocarcinoma (ICC) account for approximately 95% of all primary liver 
cancers[2,3]. However, ICC is more likely to result in a worse prognosis[4], and the 
treatment for ICC is quite different from that for HCC in specific cases. Therefore, it is 
of paramount importance to differentiate these two entities for appropriate 
intervention and better judgment of prognosis.
Over the past decade, contrast-enhanced ultrasound (CEUS) has been 
recommended as a useful tool for the characterization of focal liver lesions by several 
international professional societies in Europe and Asia[5-9]. However, CEUS was 
removed from the updated American Association for the Study of Liver Diseases 2011 
guidelines as a diagnostic technique for HCC[10] because a single-center study with a 
limited sample size reported that CEUS may misdiagnose ICC as HCC in cirrhosis 
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patients[11]. ICC is more likely to display peripheral rim arterial phase hyper- 
enhancement (APHE) followed by early and marked washout in CEUS images 
compared with HCC[12-16]. However, some studies showed that the aforementioned 
CEUS patterns may be detected in some HCC cases as well[12,13,17-19], which adds to the 
difficulty in the differential diagnosis between the two entities.
The America College of Radiology released CEUS liver imaging reporting and data 
system (LI-RADS) for standardizing CEUS diagnosis of liver nodules in patients at risk 
for HCC[19,20]. In this system, the LR-M category represents malignancies but is not 
specific for HCC[20]. However, previous studies revealed a high sensitivity of LR-M 
criteria for diagnosing non-HCC malignancy but a quite low positive predictive value 
(PPV) because of a high proportion of HCC in this category[15,17,21]. Until now, the 
diagnostic accuracy of LR-M criteria in differentiating ICC and LR-M HCC (defined as 
HCC, categorized as LR-M according to CEUS LI-RADS) has not been fully studied. 
Hence, this study focused on analyzing the CEUS features of ICC and LR-M HCC and 
further evaluating the possibility and efficacy of LR-M criteria in differentiation 
between them. We also associated CEUS patterns with tumor markers to investigate 
the potential diagnostic efficacy.
MATERIALS AND METHODS
This retrospective study was approved by the institutional review board of West 
China Hospital of Sichuan University, and the requirement of written informed 
consent from patients was waived.
Patient selection
Patients with complete CEUS records together with pathologically confirmed ICC and 
LR-M HCC between January 2015 and October 2018 were included in this 
retrospective study. The patient selection flow chart is presented in Figure 1. In case of 
multiple lesions, the dominant tumor was chosen for analysis. Therefore, a total of 228 
lesions were collected for analysis in this study.
Ultrasound examination
All enrolled patients underwent conventional ultrasound and CEUS examinations 
using a Philips IU 22 system (Philips Medical Solutions; Mountain View, CA, United 
States) with a C5-1 MHz convex transducer. The CEUS study was performed after 
conventional ultrasound examination of the liver. A 1.2-2.4-mL bolus injection of 
sulfur hexafluoride-filled microbubble contrast agent (SonoVue; Bracco, Milan, Italy) 
was administered via a 20-gauge angiocatheter needle placed in the antecubital vein, 
followed by flushing with 5 mL of 0.9% sodium chloride solution. After the 
completion of the SonoVue injection, the imaging timer was initiated simultaneously. 
The still images and video clips of CEUS examination were digitally stored for further 
evaluation.
Image analysis
The CEUS images were numbered randomly after deidentification and then reviewed 
by two radiologists (WL and JL) with more than 5 years of experience in liver CEUS 
examination independently. Both radiologists were blinded to the clinical information 
of the patients. Arterial phase enhancement, presence or absence of early washout, and 
washout degree of the liver nodules were analyzed. The APHE pattern refers to lesions 
that manifest as hyperechoic when compared with the surrounding liver parenchyma 
in the arterial phase. Rim APHE is a sub-type of APHE, where the enhancement is 
most pronounced in the periphery of the lesion. Washout refers to a lesion that 
presents a reduction in enhancement either in whole or in part vs the surrounding liver 
parenchyma. Washout that occurs within 60 s is further termed “early washout”; 
otherwise, it is termed “late washout”. Marked washout is defined as a lesion that is 
virtually devoid of enhancement (so-called “punch-out”) within 120 s after contrast 
injection[22]. The enhancing feature of each lesion was analyzed, and the lesions were 
further classified into relevant categories according to the CEUS LI-RADS (2017 
version) by both radiologists. If there was a discrepancy between the radiologists, 
arbitration from another senior radiologist (QL) with more than 10 years of experience 
in liver CEUS examination was performed. Meanwhile, the CEUS imaging features of 
lesions were recorded for further analysis.
Huang JY et al. Differentiating intrahepatic cholangiocarcinoma from hepatocellular carcinoma
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Figure 1  Flow chart of participant inclusion. CEUS: Contrast-enhanced ultrasound; HCC: Hepatocellular carcinoma; ICC: Intrahepatic cholangiocarcinoma.
Statistical analysis
Quantitative data are presented as the mean ± SD, and qualitative data are presented 
as absolute numbers and percentages. Enhancing patterns of the nodules in CEUS 
were compared by using the χ2 test, while quantitative variables were compared using 
student’s t test and the Mann-Whitney test. Logistic regression was used to predict the 
correlation between LR-M characteristics, serum tumor markers, and ICC or LR-M 
HCC. The diagnostic capability of CEUS and tumor markers in differentiating between 
ICC and LR-M HCC was analyzed by receiver operating characteristic (ROC) curve 
analysis. The cut-off values of 100 U/mL and 20 ng/mL were used for the elevation of 
carbohydrate antigen 19-9 (CA 19-9) and alpha fetoprotein (AFP), respectively, as 
recommended by previous studies[23-27]. Interobserver agreement was evaluated by the 
two radiologists by calculating the κ-value. A κ value < 0.2 indicates poor agreement, 
0.21 to 0.40 indicates fair agreement, 0.41 to 0.60 indicates moderate agreement, 0.61 to 
0.80 indicates good agreement, and 0.80 to 1 indicates almost perfect agreement. 
Significance was defined as P < 0.05. Statistical analyses were performed using a 
statistical software package (MedCalc10.4.7.0, Ostend, Belgium).
RESULTS
A total of 228 patients with 228 pathologically confirmed lesions, including 99 ICCs 
and 129 LR-M HCCs, were included in this study. The clinicopathological data of the 
patients, including age, gender, nodule size, etiology, tumor markers, fibrosis stage, 
and pathological results, are presented in Table 1.
Interobserver agreement regarding the review of enhancing patterns in the arterial 
phase and portal/late phase showed good consistency, with κ values of 0.72 and 0.88, 
respectively. The tissue sample used for histological evaluation was obtained from 
surgical resection or percutaneous biopsy. Liver cirrhosis was found in 2% (2/99) of 
ICCs and 46.5% (60/129) of HCCs (P < 0.001). Chronic hepatitis B (CHB) was detected 
in 20.2% (20/99) of ICCs and 88.4% (114/129) of HCCs (P < 0.001), and intrahepatic 
duct dilatation was present in 17.2% (17/99) of ICCs vs 2.3% (3/129) of HCCs (P < 
0.001). In terms of tumor differentiation, poor, moderate, and well differentiation was 
found in 52.7% (68/129), 45.7% (59/129), and 1.6% (2/129) of LR-M HCCs, 
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Table 1 Demographic and clinicopathological information of 228 enrolled patients, n (%)
Pathology
Patient characteristic
ICC (n = 99) LR-M HCC (n =129)
P value
Age, mean ± SD, (range), yr 59 ± 10.2 (57-61) 52 ± 12.8 (50-54) = 0.017
Sex
Male 51 (51.5) 107 (82.9) < 0.001
Female 48 (48.5) 22 (17.1) -
Nodule size, mean ± SD, (range), cm 6.3 ± 2.8 (5.7-6.8) 5.5 ± 3.5 (4.9-6.1) 0.03
Intrahepatic bile duct dilatation 17 (17.2) 3 (2.3) 0.001
CA 19-9 (U/mL) 74.0 (41.9-136.5) 18.8 (16.0-22.0) < 0.001
AFP (ng/mL) 3.0 (2.7-3.5) 67.3 (18.0-146.7) < 0.001
Etiology
HBV 20 (20.2) 114 (88.4) < 0.001
HCV 1 (1) 2 (1.5) > 0.05
Intrahepatic cholelithiasis 4 (4) 0 (0) > 0.05
Fatty liver 0 5 (3.9) > 0.05
Unknown 74 (74.7) 2 (1.5) < 0.001
Fibrosis stage
S1 3 (3) 4 (3.1) > 0.05
S2 7 (7.1) 16 (12.4) > 0.05
S3 4 (4) 20 (15.5) 0.009
S4 2 (2) 60 (46.5) < 0.001
Unclassified 83 (83.8) 29 (22.5) -
Tumor tissue differentiation
Well differentiated 1 (1) 2 (1.5) -
Moderately differentiated 21 (21.2) 59 (45.7) -
Poorly differentiated 77 (77.8) 68 (52.7) -
ICC: Intrahepatic cholangiocarcinoma; HCC: Hepatocellular carcinoma; AFP: Alpha fetoprotein; CA 19-9: Carbohydrate antigen 19-9; HBV: Hepatitis B 
virus; HCV: Hepatitis C virus; SD: standard deviation.
respectively. Regarding the tumor markers, CA 19-9 was significantly higher in ICC 
than in LR-M HCC [74.0 (41.9-136.5) U/mL vs 18.8 (16.0-22.0) U/mL, P < 0.001], while 
AFP was significantly lower in ICC than in LR-M HCC [3.0 (2.7-3.5) ng/mL vs 67.3 
(18.0-146.7) ng/mL, P < 0.001].
CEUS features of ICC and LR-M HCC
The CEUS image characteristics of ICC and LR-M HCC, including arterial phase 
enhancement pattern, washout onset timing, and washout degree are presented in 
Table 2. In the arterial phase, three types of enhancing patterns were illustrated: 
Homogeneous hyperenhancement, heterogeneous hyperenhancement, and rim 
hyperenhancement. Rim APHE was detected in 50.5% (50/99) of ICCs vs 16.3% 
(21/129) of LR-M HCCs (P  < 0.0001) (Figure 2-4). Arterial homogeneous 
hyperenhancement was observed in 15.2% (15/99) of ICCs and 37.2% (48/129) of LR-
M HCCs (P = 0.0004) (Figure 5). Early washout of contrast agent was illustrated in 
93.4% (93/99) of ICCs vs 96.1% (124/129) of LR-M HCCs (P > 0.05). Marked washout 
of contrast agent within 120 s was shown in 23.2% (23/99) of ICCs vs 7.8% (10/129) of 
HCCs (P = 0.002). Of note, this feature did not show up alone in either of the two 
entities.
A comparison of the LR-M features between ICC and LR-M HCC is presented in 
Table 3. Rim APHE followed by early washout was the most frequent combination of 
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Table 2 Pre-contrast and contrast-enhanced ultrasound features of 228 lesions, n (%)
Pathology
Imaging characteristic
ICC (n = 99) LR-M HCC (n = 129)
P value
Gray scale echogenicity
Hyperechoic 4 (4) 39 (30.0) < 0.001
Hypoechoic 93 (93.9) 82 (63.1) < 0.001
Mixed 2 (2) 8 (6.9) > 0.05
APHE
Homogeneous 15 (15.2) 48 (37.2) < 0.001
Heterogeneous 34 (34.3) 60 (46.5) > 0.05
Rim 50 (50.5) 21 (16.3) < 0.001
Early washout (onset < 60 s) 93 (93.4) 124 (96.1) > 0.05
Marked washout within 120 s 23 (23.2) 10 (7.8) = 0.002
ICC: Intrahepatic cholangiocarcinoma; HCC: Hepatocellular carcinoma; APHE: Arterial phase hyperenhancement.
LR-M features, which was detected in 30.3% (30/99) of ICCs vs 10.1% (13/129) of LR-
M HCCs (P = 0.0002). The presence of all three LR-M features in a nodule also showed 
a significant difference between the two entities (P = 0.0018).
Taking rim APHE, early washout,  marked washout,  homogeneous 
hyperenhancement, CA 19-9, and AFP as independent variables, the regression 
analysis showed that rim APHE, CA 19-9, and AFP had significant correlations with 
ICC (r = 1.251, 3.075, and -2.767, respectively; P < 0.01). ROC curve analysis for the 
diagnostic performance of LR-M characteristics in differentiating ICC from LR-M HCC 
is presented in Table 4. Rim APHE presented the best diagnostic performance for ICC, 
and the area under the ROC curve (AUC) was 0.70 [95% confidence interval (CI): 0.63-
0.76], with a sensitivity of 70.4% (95%CI: 58.4%-80.7%) and specificity of 68.8% (95%CI: 
60.9%-75.9%). When rim APHE was coupled with elevated CA 19-9 and normal AFP, 
the AUC and sensitivity improved to 0.82 (95% CI: 0.76-0.87) and 100% (95%CI: 86.8%-
100%), respectively, with specificity decreasing to 63.9% (95% CI: 56.8%-70.5%).
DISCUSSION
The LR-M category of CEUS LI-RADS was generated for lesions that are malignant but 
not specific to HCC[20]. There was a significantly low PPV of LR-M for the diagnosis of 
non-HCC malignancy due to a high proportion of HCC cases in this category, leading 
to the recommendation of biopsy for all CEUS LR-M lesions[28,29]. In this retrospective 
study, we focused on ICC and LR-M HCC, which composed the majority of LR-M 
lesions, expecting to achieve a better understanding of the differential diagnosis 
between the two entities. Our study demonstrated that rim APHE and marked 
washout were more frequently observed in ICCs than in LR-M HCCs (50.5% vs 16.3% 
and 23.2% vs 7.8%, respectively; P < 0.01). Although early washout was the most 
common feature in both ICCs and LR-M HCCs, the rate difference of this feature 
between the two entities was not significant. Marked washout did not show up alone 
either in ICC or in LR-M HCC. Of note, rim APHE was a key feature, which showed a 
significant positive correlation with ICCs in our study. The AUC, sensitivity, and 
specificity of rim APHE for the differential diagnosis was 0.70, 70.4%, and 68.8%, 
respectively. When rim APHE was coupled with elevated CA 19-9 and normal AFP, 
the AUC and sensitivity improved to 0.82 and 100%, with specificity decreasing to 
63.9%.
Rim APHE was a symbolic wash-in pattern of ICC detected in 50.5% of ICC cases in 
the present study, which was in accordance with the rates of 43%-68.5% in previous 
reports[12-14,18]. Serum biomarkers, especially AFP and CA19-9, have been proven to be 
helpful for the diagnosis of HCC and ICC. In the study conducted by Chen et al[12], the 
investigators added CA 19-9 to their CEUS score nomogram to enhance the 
discriminatory power of the predictive model for the differentiation between ICC and 
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Table 3 Comparison of the LR-M features between intrahepatic cholangiocarcinoma and LR-M hepatocellular carcinoma
Rim APHE + late and mild 
washout
APHE + early and mild 
washout
APHE + late and marked 
washout
Rim APHE + early and 
marked washout
Rim APHE + early and 
mild washout
Rim APHE + late and 
marked washout
APHE + early and marked 
washoutχ2 test
ICC LR-M HCC ICC LR-M HCC ICC LR-M HCC ICC LR-M HCC ICC LR-M HCC ICC LR-M HCC ICC LR-M HCC
Positive 4 5 42 101 0 0 14 3 30 13 2 0 7 7
Negative 95 124 57 28 99 129 8 126 9 116 97 129 92 122
Proportion(%) 4 3.9 42.4 78.3 0 0 14.1 2.3 30.3 10.1 2 0 7.1 5.4
P value > 0.05 < 0.0001 - 0.0018 0.0002 > 0.05 > 0.05
95%CI -5.6%-6.6% 22.8%-47.8% - 4.3%-20.4% 9.2%-31.3% -1.3%-7.1% -5.2%-9.4%
ICC: Intrahepatic cholangiocarcinoma; HCC: Hepatocellular carcinoma; CEUS: Contrast enhanced ultrasound; LI-RADS: Liver imaging reporting and data system. APHE: Arterial phase hyperenhancement; 95% CI: 95% confidence 
interval.
HCC. We found that when using rim APHE plus CA 19-9 for the differential 
diagnosis, the AUC and sensitivity improved from 0.70 to 0.82 and 70.4% to 100%, 
respectively. However, rim APHE could be influenced by multiple factors, including 
tumor size, pathological constitution of a lesion, and liver background[18,30,31]. Small 
ICCs, especially those ≤ 2 cm, are rich in tumor cells with few fibrous tissues and no 
central necrosis[32], thus potentially mimicking the homogeneous hyperenhancement 
pattern of HCC[14,19,33,34]. Meanwhile, ICC showing rim APHE was more likely to be 
detected in livers without cirrhosis and chronic viral hepatitis [19,30,31,33]. In our study, 
chronic hepatitis B and cirrhosis were both more frequent in patients with LR-M HCCs 
than in those with ICCs (88.4% vs 20.2% and 46.5% vs 2%, respectively; P < 0.001). 
Similarly, in a recent study by Li et al[18], the authors proved that there was no 
significant difference in rim APHE, early washout, or marked washout between ICC 
patients with and without risk factors. All of these features were more frequent in 
ICCs than in HCCs, regardless of the risk factors].
In terms of washout pattern, previous studies indicated that ICC is prone to wash 
out earlier than HCC[12,13,15,34]. Although early washout was the most frequent feature of 
both ICCs and LR-M HCCs in this study, no significant difference was found in the 
rates of early washout between the two entities. This discrepancy may result from the 
difference in study subjects, as this study focused on LR-M HCC, which presented 
specific imaging features compared with typical HCC. The feature of washout within 
60 s per LR-M criteria may be the primary reason why a substantial number of HCCs 
were classified as LR-M. In our study, 96.1% (124/129) of LR-M HCCs presented early 
washout, which is close to the results of 96% (214/224) in the study of Zheng et al[21]. 
Liu et al[13] found that the average washout time of ICCs was 27.5 s, compared with 70.1 
s for HCCs (P < 0.05). Li et al[18] also reported that 90.7% and 92.7% of ICCs in patients 
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Table 4 The receiver operating characteristic curve analysis for diagnostic performance of contrast-enhanced ultrasound liver imaging 
reporting and data system LR-M characteristics in differentiation intrahepatic cholangiocarcinoma and LR-M hepatocellular carcinoma
Criterion AUC 95%CI Sensitivity(%) 95%CI Specificity (%) 95%CI +LR 95%CI -LR 95%CI
Rim APHE 0.7 0.63-0.76 70.4 58.4-80.7 68.8 60.9-75.9 2.3 1.9-2.7 0.4 0.3-0.7
Early washout 0.56 0.49-0.62 57.1 50.3-63.8 54.6 23.4-83.3 1.3 0.7-2.2 0.8 0.4-1.5
Marked washout 0.65 0.59-0.72 69.7 51.3-84.4 61 53.8-67.9 1.8 1.4-2.3 0.5 0.3-0.9
Rim APHE + 
elevated CA 19-9 + 
normal AFP
0.82 0.76-0.87 100 86.8-100 63.9 56.8-70.5 2.8 2.5-3.1 - -
ROC: Receiver operator characteristic curve; AUC: Area under curve; ICC: Intrahepatic cholangiocarcinoma; HCC: Hepatocellular carcinoma; CA 19-9: 
Carbohydrate antigen 19-9; AFP: Alpha fetoprotein; CEUS: Contrast enhanced ultrasound; LI-RADS: Liver imaging reporting and data system; APHE: 
Arterial phase hyperenhancement; 95% CI: 95% confidence interval; +LR: Positive likelihood ratio; -LR: Negative likelihood ratio.
Figure 2  A 54-year-old female patient with a lesion categorized as LR-M. A: Conventional grayscale ultrasound detected a hypoechoic nodule (arrow) 
3.6 cm in diameter in the right lobe of the liver; B: Rim arterial phase hyperenhancement (APEH) (arrow) in the arterial phase was demonstrated by contrast-
enhanced ultrasound; C and D: No washout (arrow) was observed in the early portal phase (by 60 s), and no marked washout (arrow) was observed by 126 s after 
SonoVue injection. This lesion was designated as LR-M because of rim APEH in the arterial phase; E: Poorly differentiated intrahepatic cholangiocarcinoma was 
confirmed by histopathology (hematoxylin and eosin staining, × 200).
with and without risk factors, respectively, presented washout within 45 s. Thus, the 
early washout setting in LR-M may need to be further modified to address a 
considerable number of misdiagnosed HCCs.
Marked washout of contrast agent within 120 s was found more frequently in ICCs 
than in LR-M HCCs (P = 0.002) in this study. At the time point of 2 min, only 23.2% of 
the ICCs in our study showed marked washout, which is close to the rate of 25% 
reported by Han et al[15]. Some studies also demonstrated that the efficacy of marked 
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Figure 3  A 46-year-old female patient with an LR-M lesion. A: A hypoechoic nodule (arrow) measuring 4.7 cm in diameter was identified in the left lobe of 
the liver by conventional grayscale ultrasound; B: Peripheral rim-like arterial phase hyperenhancement (arrow) in the arterial phase was demonstrated by contrast-
enhanced ultrasound; C: Early washout (arrow) was observed in the portal phase; D: No marked washout (arrow) was displayed until 155 s after SonoVue injection; 
E: Poorly differentiated ICC was confirmed by histopathology (hematoxylin and eosin staining, × 200).
washout in differentiating ICC from HCC can only be slightly improved even by 
postponing the onset time of marked washout to 3 min[15,18]. Zheng et al[21] found 142 
out of 153 LR-M nodules showing early washout within 60 s and without punch-out 
before 5 min were HCCs. The authors re-categorized lesions showing the 
aforementioned washout patterns into LR-5, and the specificity and PPV of LR-M as a 
predictor of non-HCC malignancy were remarkably improved from 88% to 96% and 
36% to 58%, respectively (P < 0.001). In our study, marked washout within 2 min did 
not show up alone in both entities. Thus, this feature in LR-M criteria may need to be 
refined for better practical application.
There are several limitations of our study. First, due to the limited number of ICC 
cases, CEUS LI-RADS was applied in patients without risk factors for HCC. In clinical 
practice, chronic hepatitis or cirrhosis would not present in the majority of ICC 
patients. However, the LR-M features enabled the differentiation of ICC from LR-M 
HCC in our study, as also validated by Li et al[18]. Second, the scope of the study 
focused only on ICC and LR-M HCC. Other hepatic malignancies, such as combined 
hepatocellular-cholangiocarcinoma and metastasis, which also frequently present as 
LR-M tumors, were not enrolled in our study. Further studies are needed to validate 
the findings demonstrated in our study and determine, for example, how much 
referential value marked washout offers the LR-M category in the absence of arterial 
phase rim APHE and early washout and whether the onset time of early washout and 
marked washout should be adjusted to reduce the number of HCCs classified as LR-M 
tumors.
In conclusion, rim APHE is a key predictor for differentiating ICC from LR-M HCC. 
Rim APHE plus elevated CA 19-9 and normal AFP is a strong predictor of ICC rather 
than LR-M HCC. Early washout and marked washout have limited value for the 
differentiation between the two entities.
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Figure 4  Contrast-enhanced ultrasound examination of a 68-year-old male patient with chronic hepatitis B infection. A: Conventional 
grayscale ultrasound demonstrated a mixed echo nodule (arrow) measuring 3.0 cm in diameter in the left lobe of the liver; B: Contrast-enhanced ultrasound illustrated 
rim arterial phase hyperenhancement (arrow) in the arterial phase; C: Early washout of the contrast agent within 60 s was observed (arrow); D: Late-phase imaging 
demonstrated marked contrast washout (arrow) within 120 s. The lesion was classified as LR-M due to the aforementioned features; E: The nodule was revealed to 
be poorly differentiated hepatocellular carcinoma by histopathology (hematoxylin and eosin staining, × 400).
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Figure 5  A 69-year-old female patient with an LR-M lesion. A: A hypoechoic nodule measuring 3.2 cm in diameter (arrow) was observed by conventional 
grayscale ultrasound in the left lobe of the liver; B: Contrast-enhanced ultrasound illustrated homogeneous hyperenhancement (arrow) in the arterial phase; C: Early 
washout was demonstrated (arrow) at 60 s after SonoVue injection; D: No marked washout (arrow) was observed by 120 s; E: This lesion was classified as LR-M, 
and moderately differentiated intrahepatic cholangiocarcinoma was confirmed by histopathology (hematoxylin and eosin staining, × 200).
ARTICLE HIGHLIGHTS
Research background
Liver cancer is the sixth most common cancer worldwide and the fourth leading cause 
of cancer-related death. Hepatocellular carcinoma (HCC) and intrahepatic 
cholangiocarcinoma (ICC) account for the majority of all primary liver cancers and 
differ in treatment and prognosis.
Research motivation
Contrast-enhanced ultrasound (CEUS) has been recommended and widely used for 
the characterization of focal liver lesions. However, the value of CEUS in 
differentiating between ICC and HCC remains controversial. The CEUS liver imaging 
reporting and data system (LI-RADS) released by the American College of Radiology 
has been developed for standardizing CEUS criteria for the diagnosis of focal liver 
lesions. In the criteria, the LR-M category represents malignancies but is not specific to 
HCC. Of note, the presence of a substantial number of HCCs in this category elevates 
the difficulty in the differential diagnosis between ICC and HCC, and the efficacy of 
LR-M features for the differentiation between them has not yet been fully evaluated.
Research objectives
The purpose of this study was to investigate the possibility and efficacy of 
differentiating ICC from HCC classified in the LR-M category according to the CEUS 
LI-RADS.
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Research methods
Patients with complete CEUS records together with pathologically confirmed ICC and 
LR-M HCC (HCC classified in the CEUS LI-RADS LR-M category) between January 
2015 and October 2018 were included in this retrospective study. Each ICC was 
assigned a category as per the CEUS LI-RADS. The enhancement pattern, washout 
timing, and washout degree between the ICC and LR-M HCC were compared using 
the χ2 test. Logistic regression analysis was used for prediction of ICC. Receiver 
operating characteristic curve analysis was used to investigate the possibility of LR-M 
criteria and serum tumor markers in differentiating ICC from LR-M HCC.
Research results
A total of 228 nodules (99 ICCs and 129 LR-M HCCs) in 228 patients were included. 
The mean sizes of ICC and LR-M HCC were 6.3 ± 2.8 cm and 5.5 ± 3.5 cm, respectively 
(P = 0.03). Peripheral rim-like arterial phase hyperenhancement (rim APHE) was 
detected in 50.5% (50/99) of ICCs vs 16.3% (21/129) of LR-M HCCs (P < 0.001). Early 
washout was found in 93.4% (93/99) of ICCs vs 96.1% (124/129) of LR-M HCCs (P > 
0.05). Marked washout was observed in 23.2% (23/99) of ICCs and 7.8% (10/129) of 
LR-M HCCs (P = 0.002), while this feature did not show up alone either in ICC or LR-
M HCC. Homogeneous hyperenhancement was detected in 15.2% (15/99) of ICCs and 
37.2% (48/129) of LR-M HCCs (P < 0.001). The logistic regression showed that rim 
APHE, carbohydrate antigen 19-9 (CA 19-9), and alpha fetoprotein (AFP) exhibited 
significant correlations with ICC (r = 1.251, 3.074, and -2.767, respectively; P < 0.01). 
Rim APHE presented the best enhancement pattern for diagnosing ICC, with an area 
under the receiver operating characteristic curve (AUC) of 0.70, sensitivity of 70.4%, 
and specificity of 68.8%. When rim hyperenhancement was coupled with elevated CA 
19-9 and normal AFP, the AUC and sensitivity improved to 0.82 and 100%, 
respectively, with specificity decreasing to 63.9%.
Research conclusions
This study illustrated that rim APHE is a key predictor for differentiating ICC from 
LR-M HCC. Rim APHE plus elevated CA 19-9 and normal AFP is a predictor of ICC 
rather than LR-M HCC. Early washout and marked washout have limited value for 
the differentiation between the two entities.
Research perspectives
Rim APHE is a key predictor for differentiating ICC from LR-M HCC, and rim APHE 
plus elevated CA 19-9 and normal AFP is a predictor of ICC rather than LR-M HCC. 
The reference values of early washout (< 60 s) and marked washout within 120 s in the 
LR-M category are needed to further refine the CEUS LI-RADS criteria to avoid 
unnecessary biopsy.
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